secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLIGENIX, INC. (SNGX)
CIK:        0000812796
Form:       8-K
Filed at:   2022-10-25T23:59:59+00:00
Accession:  0001558370-22-015319
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soligenix forms Psoriasis Medical Advisory Board; Phase 2a study starts December 2022
--------------------------------------------------------------------------------

- Formed Medical Advisory Board (MAB) for SGX302 (synthetic hypericin) in mild-to-moderate psoriasis.
- Phase 2a clinical study anticipated to begin in December 2022; FDA previously cleared IND and protocol.
- MAB chaired by Neal Bhatia, MD (Therapeutics Clinical Research, San Diego).
- Previous positive Phase 3 trial of HyBryte (same synthetic hypericin) in CTCL supports psoriasis program.
- Psoriasis affects >7.5 million patients in the U.S.; MAB includes four board-certified dermatologists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/812796/000155837022015319/0001558370-22-015319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/812796/000155837022015319/tmb-20221025x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-015319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer